Development and Pharmacological Evaluation of Novel Oral Amphotericin B Formulations for the Treatment of Experimental Systemic Fungal Infections: Providing New Therapeutic Approach for an Unmet Medical Need in First and Third World Countries

Amphotericin B is the most effective, and frequently the only treatment available for a number of life-threatening diseases, including systemic fungal infections and visceral leishmaniasis. The drawbacks of today’s amphotericin B treatment are toxicity and the need to administer the drug intravenously in hospital settings. The need for intravenous administration is due to poor absorption of the drug following oral administration and greatly increases the costs of the therapy and complications associated with intravenous admnistration.